Phase 3 Readout~month

Phase 3 Topline: A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib

Indication
Metabolic Syndrome (MetS); Type 2 Diabetes (T2DM); Lipidemia

Other upcoming events for NAMS

Phase 3 ReadoutPhase 3 Topline: A Placebo-controlled, Double-blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib/
Patent ExpiryPatent/Exclusivity Expiry: ROSZET
Patent ExpiryPatent/Exclusivity Expiry: EZALLOR SPRINKLE
Patent ExpiryPatent/Exclusivity Expiry: ATORVALIQ

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib — NAMS Phase 3 Readout | BioSniper